Filing Flows › Regenxbio (RGNX) › Q3 2026 › vs Q2 2026
Regenxbio (RGNX) Q3 2026 vs Q2 2026 (quarter over quarter)
Regenxbio's revenue fell $98.9M (-92%) from $108M in Q2 2026 to $9.2M in Q3 2026.
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 419.3% | -58.3% | +477.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.2M | $108M | −$98.9M | -92% |
| Net loss | $40.7M | −$22.7M | $63.4M | — |
| Costs & expenses | $49.9M | $108M | −$58.1M | -54% |
| Operating costs | $44.7M | $78.8M | −$34.1M | -43% |
| Interest & other, net | $5.2M | $6.6M | −$1.4M | -21% |
| Operating cash sources | $79.3M | −$84.9M | $164M | — |
| Depreciation & amortization | $3.5M | $3.8M | −$242K | -6% |
| Share-based compensation | $8.1M | $9.1M | −$933K | -10% |
| Working capital & other | $67.7M | −$97.8M | $165M | — |
| Net loss absorbed | $40.7M | −$22.7M | $63.4M | — |
| Operating cash flow | $38.6M | −$62.2M | $101M | — |
| Free cash flow (OCF − capex) | $38.4M | −$63.0M | $101M | — |
| Capital expenditures | $194K | $760K | −$566K | -74% |
Questions
How much did Regenxbio's revenue grow quarter over quarter in Q3 2026?
Regenxbio's revenue fell $98.9M (-92%) from $108M in Q2 2026 to $9.2M in Q3 2026.